Antisense modulation of B7 protein expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsC. Frank Bennett, Timothy A. Vickers, James G. Karras
Life of this patent
Estimating the term…
Abstract
Compositions and methods for the diagnosis, prevention and treatment of immune states and disorders amenable to treatment through modulation of T cell activation are provided. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding B7 proteins.
Claims40
An antisense compound 20 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human B7, said compound comprising SEQ ID NO:
- 256.
A composition comprising an antisense compound consisting of SEQ ID NO:
- 256.
A composition comprising an antisense compound comprising SEQ ID NO:
- 256, wherein every internucleoside linkage is a phosphorothioate linkage, and nucleobases 1–5 and 16–20 comprise a 2′-O-methoxyethyl modification.
A composition comprising an antisense compound consisting of SEQ ID NO:
- 256, wherein every internucleoside linkage is a phosphorothioate linkage, and nucleobases 1–5 and 16–20 comprise a 2′-O-methoxyethyl modification.
A composition comprising an antisense compound consisting of SEQ ID NO:
- 256, wherein every internucleoside linkage is a phosphorothioate linkage, nucleobases 14 and 15–18 comprise a 2′-O-methoxyethyl modification, and cytidine residues at positions 5 and 10 comprise a 5-methyl modification.
Dependencies are inferred from the claim text.